(Q35636708)

English

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis

scientific article published on 13 July 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis (English)

1 reference

Europe PubMed Central

9 August 2017

ankylosing spondylitis

1 reference

based on heuristic

inferred from title

0 references

Désirée van der Heijde

2

object named as

D van der Heijde

1 reference

Europe PubMed Central

9 August 2017

author name string

A Boonen

1

1 reference

Europe PubMed Central

9 August 2017

J L Severens

3

1 reference

Europe PubMed Central

9 August 2017

A Boendermaker

4

1 reference

Europe PubMed Central

9 August 2017

R Landewé

5

1 reference

Europe PubMed Central

9 August 2017

J Braun

6

1 reference

Europe PubMed Central

9 August 2017

J Brandt

7

1 reference

Europe PubMed Central

9 August 2017

J Sieper

8

1 reference

Europe PubMed Central

9 August 2017

Sj van der Linden

9

1 reference

Europe PubMed Central

9 August 2017

language of work or name

0 references

publication date

13 July 2005

1 reference

Europe PubMed Central

9 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

9 August 2017

65

1 reference

Europe PubMed Central

9 August 2017

2

1 reference

Europe PubMed Central

9 August 2017

201-208

1 reference

Europe PubMed Central

9 August 2017

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

12 July 2018

Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

12 July 2018

Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

12 July 2018

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

12 July 2018

Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

12 July 2018

Costs of ankylosing spondylitis in three European countries: the patient's perspective.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

12 July 2018

Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

12 July 2018

Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

12 July 2018

Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

12 July 2018

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

12 July 2018

Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

12 July 2018

Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

12 July 2018

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

12 July 2018

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

25 September 2018

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

25 September 2018

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

25 September 2018

Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1798006

15 November 2018

Uncertainty of incremental cost-effectiveness ratios. A comparison of Fieller and bootstrap confidence intervals

1 reference

https://pubmed.ncbi.nlm.nih.gov/16014677

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument?

1 reference

https://pubmed.ncbi.nlm.nih.gov/16014677

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab treatment of severe ankylosing spondylitis: one-year followup

1 reference

https://pubmed.ncbi.nlm.nih.gov/16014677

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/16014677

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety

1 reference

https://pubmed.ncbi.nlm.nih.gov/16014677

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost effectiveness of combined spa-exercise therapy in ankylosing spondylitis: A randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16014677

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16014677

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16014677

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A practical guide for calculating indirect costs of disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/16014677

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ARD.2004.032565

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35636708&oldid=1543843929"